MedTrace Logo

HD16 for Early Stage Hodgkin Lymphoma

NCT00736320 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1150

Last updated 2020-11-04

No results posted yet for this study

Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).

Conditions

Interventions

DRUG

ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)

chemotherapy with 2 cycles of ABVD (day 1 + 15)

RADIATION

20 Gy IFRT (Involved Field Radiotherapy)

20 Gy Involved Field Radiotherapy

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof. · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2018-09-30
Completion
2021-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736320 on ClinicalTrials.gov